Recent advances in cancer immunology have revealed the importance of signaling between Programmed Death–1 (PD-1), expressed on antigen-experienced T cells, and its ligand PD-L1, expressed on antigen presenting cells and tumor cells (TCs) [9]. This evidence concerns the gene RPL17 and cancer.